Yep, the CEO genuinely said KRM-ll-81 is "remarkable" and considering the advancement inside of the high profile NIH HEAL, that is extremely valuable.
How many people think the CEO referenced "purse strings" would be looking to keep that asset on the OTC? My question would 200-300M be enough? I think it is logical that BP would secure rights to all pain indications coming out of the NIH HEAL program. They stated applying for IND enablement funds for epilepsy indication. Same BP or another get involved? Maybe the gabakine program becomes a new entity with multiple BP investors/partners?
Market Data 
Markets 
AI
